ARA is an essential fatty acid for the development of infants and young children
Recent headlines have warned women that vitamin supplements in pregnancy are a “pointless waste of money,” seemingly discouraging micronutrient supplementation at this crucial time. Check the story behind the headlines.
Professor Cashman is the joint coordinator of the EU-funded ODIN project. He is lead author of a new paper that the authors say provides “firm evidence” of the significant risk that vitamin D deficiency poses to public health in the EU. They found that 13% of the cohort of 55,844 individuals drawn from across Europe had serum vitamin D levels below 30 nmol/L.
Professor Oleg Shadyro of the Department of Chemistry at the University of Belarus has shown that coenzyme Q10 and vitamins are able to down-regulate the cellular production of phosphatidic acid (PA) in low cellular oxygen conditions which would otherwise inhibit normal cell apoptosis. Hence supplementation with these substances could improve the efficacy of radiotherapy or chemotherapy.
Professor David Kennedy, Director of the Brain, Performance and Nutrition Research Centre at Northumbria University, makes a convincing argument in his new review paper that in the absence of an optimal diet, all eight B vitamins should be supplemented at doses in excess of current UK government recommendations if optimal brain health is to be achieved.
Professor Celeste de Jager of the Division of Geriatric Medicine at the University of Cape Town, South Africa, specializes in the effect of nutrition on cognitive decline in the elderly. In recent years, she has been closely involved in the VITACOG randomized controlled trial which found that a vitamin B intervention reduced circulating homocysteine levels, leading to a reduced rate of cognitive decline. Her most recent paper demonstrates that this effect is dependent on the patient having omega-3 fatty acid levels in the upper-normal range.
Professor Kathryn Dewey of the Nutrition Department of the University of California, Davis, was the principal investigator of a cluster-randomized controlled effectiveness trial in Bangladesh which demonstrated that a small, lipid-based micronutrient supplement could help reduce stunting in newborn babies.
Dr. Andrew Chen, MBBS, from the Royal Prince Alfred Hospital at the University of Sydney in Australia and leader of the ONTRAC (Oral Nicotinamide to Reduce Actinic Cancer) phase 3 trial (1), says that “nicotinamide presents a new opportunity for the chemoprevention of non-melanoma skin cancers that is readily translatable into clinical practice.” Results from the ONTRAC trial with a cohort of 386 Australian adults indicate that a daily intervention dose of 500 mg nicotinamide (vitamin B3) for 12 months is protective against new cases of non-melanoma skin cancers.